Linked Life Data

17316095

Source:http://linkedlifedata.com/resource/pubmed/id/17316095

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-2-23
pubmed:abstractText
The commercially available insulin products insulin aspart injection (IAsp) and insulin glulisine injection (IGlu), used for continuous subcutaneous insulin infusion (CSII), have been compared with respect to resistance towards isoelectric insulin precipitation. Additionally, a hybrid product consisting of the insulin aspart analogue in an IGlu product composition (the hybrid product was termed IAsp (Apidra)) has been examined.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1520-9156
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
26-35
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion.
pubmed:affiliation
Department of Pharmaceutics, Diabetes, Novo Nordisk A/S, Bagsvaerd, Denmark. chpo@novonordisk.com
pubmed:publicationType
Journal Article